
AVBP
Healthcare · Biotechnology · $672.9M market cap
$13.01-0.06 (-0.5%)Nov 13, 4:00 PM EST
Next report
After the close
Analyst consensus
Fiscal period ending Dec 31, 2026
EPS trend, 90 days to now · -5.3% over 90 days · 30-day revisions 5 up, 1 down
Beat estimates in 2 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Mar 8, 2027 · upcoming | After the close | -1.10 | — | — |
| Nov 9, 2026 | After the close | -1.04 | -0.81 | +22.1% |
| Aug 12, 2026 | After the close | -0.98 | -1.05 | -7.1% |
| May 11, 2026 | After the close | -0.89 | -0.96 | -7.9% |
| Mar 26, 2026 | Time not confirmed | -0.82 | -0.78 | +4.9% |
| Nov 10, 2025 | Before the open | -0.78 | -0.83 | -6.4% |
| Aug 11, 2025 | Before the open | -0.71 | -0.90 | -26.8% |
| May 12, 2025 | Before the open | -0.69 | -1.90 | -175.4% |
| Mar 3, 2025 | Time not confirmed | -0.46 | -0.60 | -30.4% |
| Nov 14, 2024 | Before the open | -1.07 | -0.61 | +43.0% |
| Aug 14, 2024 | After the close | -0.59 | -0.65 | -10.2% |
| May 8, 2024 | Before the open | -1.30 | -0.70 | +46.2% |
| Mar 28, 2024 | After the close | -1.10 |
ArriVent BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers. The company's lead development candidate is firmonertinib, a tyrosine kinase inhibitor that is being evaluated in multiple clinical trials across a range of epidermal growth factor receptor mutations (EGFRm) in…
| -0.70 |
| +36.4% |